用于制备铜-64标记卟啉-脂质纳米颗粒的放射性药物试剂盒,以在癌症患者中开展放射性示踪成像研究
本研究将铜-64标记卟啉-脂质纳米颗粒(64Cu-PS)的标记流程优化为「一锅法」试剂盒,并在健康Fisher 344大鼠和Beagle犬中评估其血浆药代动力学、组织分布及单次和重复给药毒性,同时估算人体辐射剂量。试剂盒制备的64Cu-PS标记产率高,平均比活度为18.5 MBq/mg(最大11.4 GBq/mg);大鼠和犬中PS血浆药代动力学在0.5-15 mg/kg剂量范围内呈线性,组织分布主要至肝脏;人体估算有效剂量为38-47 µSv/MBq。大鼠单次32.6 mg/kg PS未见可检测毒性;犬中从≥10 mg/kg PS起始的单次和重复给药后观察到轻度一过性输注反应,犬中高达15 mg/kg PS的剂量可耐受。作者结论认为PS和64Cu-PS在大鼠和犬中的药理学和安全性特征未引起对其人体使用的担忧。
要点
- 64Cu-PS「一锅法」试剂盒标记产率高,平均比活度18.5 MBq/mg(最大11.4 GBq/mg)。
- 大鼠和犬中PS血浆药代动力学在0.5-15 mg/kg剂量范围内呈线性,组织分布主要至肝脏。
- 人体估算有效剂量为38-47 µSv/MBq;犬中从≥10 mg/kg PS起始给药后出现轻度一过性输注反应。
核心结论
- PS和64Cu-PS在大鼠和犬中的药理学和安全性特征未引起对其人体使用的担忧。
- 放射性标记的64Cu-PS将允许在癌症患者的成像研究中基于影像准确评估纳米颗粒的药代动力学和肿瘤摄取。
研究设计与样本
- 研究表征了PS和64Cu-PS的理化和放射化学性质,并在大鼠和犬中评估其药理学和毒理学。
- 64Cu-PS标记流程经优化并开发为「一锅法」试剂盒形式。
- 在健康Fisher 344大鼠和Beagle犬静脉注射剂量递增的PS后评估血浆药代动力学、组织分布及单次和重复给药毒性。
- 从单次64Cu-PS剂量估算人体辐射剂量。
主要发现
- 试剂盒制备的64Cu-PS具有高标记产率和平均比活度18.5 MBq/mg(最大11.4 GBq/mg)。
- PS血浆药代动力学在大鼠和犬中于0.5-15 mg/kg剂量范围内呈线性。
- 组织分布主要至肝脏。
- 人体中64Cu-PS的估算有效剂量为38-47 µSv/MBq。
- 大鼠单次32.6 mg/kg PS未见可检测毒性;犬中从≥10 mg/kg PS起始的单次和重复给药后观察到轻度一过性输注反应,犬中高达15 mg/kg PS的剂量可耐受。
关键数值与推荐
- 试剂盒制备的64Cu-PS平均比活度为18.5 MBq/mg,最大11.4 GBq/mg。
- PS血浆药代动力学线性范围为0.5-15 mg/kg(大鼠和犬)。
- 人体估算有效剂量为38-47 µSv/MBq。
- 大鼠单次32.6 mg/kg PS未见可检测毒性。
- 犬中从≥10 mg/kg PS起始给药后出现轻度一过性输注反应,高达15 mg/kg PS可耐受。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PORPHYSOMES (PS) are multifunctional porphyrin-lipid nanoparticles for fluorescence-guided photochemical tumour ablation and immune stimulation. PS can be radiolabelled with Copper-64 (64Cu-PS) to permit tracing of their whole-body distribution and uptake in tumours with nuclear imaging. Herein we characterised the physicochemical and radiochemical properties of PS and 64Cu-PS and evaluated their pharmacology and toxicology in rats and dogs. METHODS: 64Cu-PS labelling procedure was optimised and developed into a "one pot" kit format. The plasma pharmacokinetics (PK), tissue distribution, and single and repeat-dose toxicity of dose escalating PS was evaluated after intravenous injection in healthy Fisher 344 rats and Beagle dogs. Radiation dosimetry from single 64Cu-PS dose was estimated in humans. RESULTS: Kit prepared 64Cu-PS had high labelling yields and mean specific activities of 18.5 MBq/mg (11.4 GBq/mg max). The plasma PK of PS was linear between doses 0.5-15 mg/kg in both rats and dogs. Tissue distribution was primarily to the liver. The estimated effective dose from 64Cu-PS in humans was 38-47 µSv/MBq. Single doses of 32.6 mg/kg PS did not have detectable toxicities in rats. In dogs, mild transient infusion reactions were observed following single and repeat-doses of PS starting at ≥ 10 mg/kg PS. Doses up to 15 mg/kg PS were tolerated in dogs. CONCLUSIONS: The pharmacology and safety profiles of PS and 64Cu-PS in rats and dogs did not raise concerns regarding their use in humans. Radiolabelled 64Cu-PS will permit accurate imaging-based assessments of nanoparticle PK and tumour uptake in imaging studies in cancer patients.
引用
- Valic MS, Fisher CJ, Zheng M, et al. Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40676182. doi:10.1007/s00259-025-07442-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。